I-MAB (SPONS ADRS) RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHTue, 28 Apr 2026 23:08:00 +0200https://images.finanzen.net/images/finanzen_net_neu.gifI-MAB (SPONS ADRS) RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netI-MAB (spons ADRs) präsentierte das Zahlenwerk zum abgelaufenen JahresviertelFri, 10 Apr 2026 06:35:07 +0200https://www.finanzen.net/nachricht/aktien/i-mab-spons-adrs-praesentierte-das-zahlenwerk-zum-abgelaufenen-jahresviertel-15603135I-MAB (spons ADRs) lud am 07.04.2026 zur Finanzkonferenz und hat dort die Zahlen zum am 31.12.2025 abgelaufenen Jahresviertel präsentiert.I-MAB (spons ADRs) vermeldete für das abgelaufene Gesamtjahr einen ...

]]>https://www.finanzen.net/nachricht/aktien/i-mab-spons-adrs-praesentierte-das-zahlenwerk-zum-abgelaufenen-jahresviertel-15603135NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IOThu, 11 Dec 2025 07:12:00 +0100https://www.finanzen.net/nachricht/aktien/novabridge-presents-positive-ragistomig-phase-1-dose-expansion-data-at-esmo-io-15351132
  • Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, ...

    ]]>https://www.finanzen.net/nachricht/aktien/novabridge-presents-positive-ragistomig-phase-1-dose-expansion-data-at-esmo-io-15351132NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IOThu, 04 Dec 2025 13:34:00 +0100https://www.finanzen.net/nachricht/aktien/novabridge-announces-presentation-of-ragistomig-expanded-phase-1-data-at-esmo-io-15335170
    • Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance
    • The ...

      ]]>https://www.finanzen.net/nachricht/aktien/novabridge-announces-presentation-of-ragistomig-expanded-phase-1-data-at-esmo-io-15335170NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 ForwardFri, 21 Nov 2025 06:46:00 +0100https://www.finanzen.net/nachricht/aktien/novabridge-s-visara-subsidiary-appoints-distinguished-ophthalmology-leaders-as-chief-medical-officer-and-scientific-advisory-board-chair-to-drive-vis-101-forward-15303085
      • Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable ...

        ]]>https://www.finanzen.net/nachricht/aktien/novabridge-s-visara-subsidiary-appoints-distinguished-ophthalmology-leaders-as-chief-medical-officer-and-scientific-advisory-board-chair-to-drive-vis-101-forward-15303085I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech PlatformWed, 29 Oct 2025 16:15:00 +0100https://www.finanzen.net/nachricht/aktien/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-trading-effective-october-30-2025-new-brand-and-logo-to-reflect-strategic-transformation-to-a-global-biotech-platform-15140799
        • New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide
        • Strategy centers on broadening access ...

          ]]>https://www.finanzen.net/nachricht/aktien/i-mab-nasdaq-imab-transitions-to-novabridge-biosciences-nasdaq-nbp-with-trading-effective-october-30-2025-new-brand-and-logo-to-reflect-strategic-transformation-to-a-global-biotech-platform-15140799INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMABTue, 28 Oct 2025 15:00:00 +0100https://www.finanzen.net/nachricht/aktien/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-i-mab-imab-15132650

          NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ...

          ]]>          https://www.finanzen.net/nachricht/aktien/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-i-mab-imab-15132650